PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiCommercial · Coverage · Medical Policy · MS · Neurology, Family Medicine, Internal MedicineMedium impact

Qalsody (tofersen)

Act
immediately
Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

BCBS MS has classified Qalsody (tofersen) as investigational for ALS treatment, meaning claims will be denied. The drug requires prior authorization review, and services related to administration without PA approval will be considered not medically necessary.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

immediately · 4 steps
01Stop billing J1304 (tofersen injection) without prior authorization.
02Billing team must ensure all Qalsody administration requires BCBSMS PA approval before service delivery.
03Update billing system to flag J1304 as investigational and requiring PA.
04Claims without PA will be denied as not medically necessary.

Codes mentioned

J1304

Original notice

Qalsody (tofersen)
bcbsms.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account